title: Activating autoantibodies and cardiovascular disease.
abstract: Stimulating antibodies against G-protein-coupled receptors, including the β1- and β2-adrenergic receptors, the α1-adrenergic receptor, and the angiotensin II AT1 receptor, have been described, as well as activating antibodies directed at the platelet-derived growth factor receptor tyrosine kinase. Their existence and actions appear to be established. Lacking are mechanistic studies of receptor activation and translational studies to document receptor-stimulating antibodies as worthwhile therapeutic targets.
authors.affiliation: Experimental and Clinical Research Center and Max-Delbrück Center for Molecular Medicine and Charité Medical Faculty, Berlin, Germany. luft@charite.de
authors.forename: Friedrich C
authors.initials: FC
authors.lastname: Luft
mesh_terms: D000595:Amino Acid Sequence; D001323:Autoantibodies / Q000502:physiology*; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D006801:Humans; D008969:Molecular Sequence Data; D044140:Receptor, Angiotensin, Type 1 / Q000032:analysis / Q000737:chemistry / Q000276:immunology; D011943:Receptors, Adrenergic, beta / Q000276:immunology; D057170:Translational Research, Biomedical / Q000639:trends*
chemical_list: D001323:Autoantibodies; D044140:Receptor, Angiotensin, Type 1; D011943:Receptors, Adrenergic, beta